Demographic and baseline disease characteristics
| . | CD8-high (N = 7) . | CD8-low (N = 72) . | Total (N = 79) . |
|---|---|---|---|
| Characteristic | |||
| Age, years | |||
| Median (range) | 54.0 (39–70) | 60.5 (32–80) | 60.0 (32–80) |
| >65 years, n (%) | 1 (14) | 26 (36) | 27 (34) |
| Sex, n (%) | |||
| Female | 1 (14) | 35 (49) | 36 (46) |
| Male | 6 (86) | 37 (51) | 43 (54) |
| Race, n (%) | |||
| Asian | 0 | 5 (7) | 5 (6) |
| Black | 0 | 7 (10) | 7 (9) |
| White | 6 (86) | 45 (63) | 51 (65) |
| Other | 1 (14) | 15 (21) | 16 (20) |
| Ethnicity, n (%) | |||
| Hispanic | 0 | 9 (13) | 9 (12) |
| ECOG performance status at screening, n (%) | |||
| 0 | 4 (57) | 23 (32) | 27 (34) |
| 1 | 3 (43) | 47 (65) | 50 (63) |
| Missing | 0 | 2 (3) | 2 (3) |
| CD8 Cells (%) at screening | |||
| Median (range) | 22.0 (16–36) | 4.0 (0–14) | 5.0 (0–36) |
| Tumor type | |||
| Prostate (CRPC) | 0 | 12 (17) | 12 (15) |
| Head and Neck (HNCA) | 3 (43) | 6 (8) | 9 (11) |
| Colorectal (CRCA) | 0 | 7 (10) | 7 (9) |
| Sarcoma (SARC) | 0 | 7 (10) | 7 (9) |
| Ovarian (OVCA) | 1 (14) | 5 (7) | 6 (8) |
| Uterine (UTCA) | 0 | 4 (6) | 4 (5) |
| Breast (BRCA) | 0 | 3 (4) | 3 (4) |
| Hepatocellular cholangiocarcinoma (HECH) | 0 | 3 (4) | 3 (4) |
| Neuroendocrine (NEUC) | 0 | 3 (4) | 3 (4) |
| Renal (RNCA) | 1 (14) | 2 (3) | 3 (4) |
| Thyroid (THYR) | 0 | 3 (4) | 3 (4) |
| Othera | 2 (29) | 17 (24) | 19 (24) |
| Prior lines of cancer therapy | |||
| 0 | 0 | 3 (4) | 3 (4) |
| 1–2 | 3 (43) | 18 (25) | 21 (27) |
| 3–4 | 3 (43) | 19 (26) | 22 (28) |
| 5+ | 1 (14) | 32 (44) | 33 (42) |
| Received prior ICI therapy, n (%) | 3 (43) | 15 (21) | 18 (23) |
| . | CD8-high (N = 7) . | CD8-low (N = 72) . | Total (N = 79) . |
|---|---|---|---|
| Characteristic | |||
| Age, years | |||
| Median (range) | 54.0 (39–70) | 60.5 (32–80) | 60.0 (32–80) |
| >65 years, n (%) | 1 (14) | 26 (36) | 27 (34) |
| Sex, n (%) | |||
| Female | 1 (14) | 35 (49) | 36 (46) |
| Male | 6 (86) | 37 (51) | 43 (54) |
| Race, n (%) | |||
| Asian | 0 | 5 (7) | 5 (6) |
| Black | 0 | 7 (10) | 7 (9) |
| White | 6 (86) | 45 (63) | 51 (65) |
| Other | 1 (14) | 15 (21) | 16 (20) |
| Ethnicity, n (%) | |||
| Hispanic | 0 | 9 (13) | 9 (12) |
| ECOG performance status at screening, n (%) | |||
| 0 | 4 (57) | 23 (32) | 27 (34) |
| 1 | 3 (43) | 47 (65) | 50 (63) |
| Missing | 0 | 2 (3) | 2 (3) |
| CD8 Cells (%) at screening | |||
| Median (range) | 22.0 (16–36) | 4.0 (0–14) | 5.0 (0–36) |
| Tumor type | |||
| Prostate (CRPC) | 0 | 12 (17) | 12 (15) |
| Head and Neck (HNCA) | 3 (43) | 6 (8) | 9 (11) |
| Colorectal (CRCA) | 0 | 7 (10) | 7 (9) |
| Sarcoma (SARC) | 0 | 7 (10) | 7 (9) |
| Ovarian (OVCA) | 1 (14) | 5 (7) | 6 (8) |
| Uterine (UTCA) | 0 | 4 (6) | 4 (5) |
| Breast (BRCA) | 0 | 3 (4) | 3 (4) |
| Hepatocellular cholangiocarcinoma (HECH) | 0 | 3 (4) | 3 (4) |
| Neuroendocrine (NEUC) | 0 | 3 (4) | 3 (4) |
| Renal (RNCA) | 1 (14) | 2 (3) | 3 (4) |
| Thyroid (THYR) | 0 | 3 (4) | 3 (4) |
| Othera | 2 (29) | 17 (24) | 19 (24) |
| Prior lines of cancer therapy | |||
| 0 | 0 | 3 (4) | 3 (4) |
| 1–2 | 3 (43) | 18 (25) | 21 (27) |
| 3–4 | 3 (43) | 19 (26) | 22 (28) |
| 5+ | 1 (14) | 32 (44) | 33 (42) |
| Received prior ICI therapy, n (%) | 3 (43) | 15 (21) | 18 (23) |
Other tumor types include urethral (URET) and gastroesophageal (GEJC) (n = 1 each; 14%) in the CD8-high group and cervix (CVCX), gastric (GSCA), non-small cell lung (LUCA), pancreatic (PANC), pelvic (PELV), peritoneal (PRTC) (n = 2 each, 3%), hepatocellular carcinoma (HCCA), Merkel cell (NESK), penile (PENC), retroperitoneal teratoma (TERA), and papilla of vater (AMPV) (n = 1 each; 1%) in the CD8-low group.